Sanofi en discussions pour céder une participation majoritaire dans Opella Paris, 11 octobre 2024. Sanofi a annoncé aujourd'hui avoir entamé des négociations avec CD&R pour la cession ...

Communiqué de presse : Le CHMP recommande l’approbation du Dupixent dans l’UE pour le traitement de l’œsophagite à éosinophiles de l’enfant à partir de 12 mois CP : Le tolebrutinib a permis d’allonger ...

New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants Paris, . Sanofi advances its ambition to protect ...

John Sundy is currently Chief Medical Officer and Head of Research and Development at Seicmic Therapeutic, a machine learning immunology company and is Adjunct Professor of Medicine in the Division of ...

Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on ...

100% of developing countries work towards the UNFCCC goal of having their NAPs in place by 2025, with all new NAPs including specific health targets reflecting national and sub-national priorities.

100 % des pays en développement œuvrent pour atteindre l'objectif de la CCNUCC d'avoir leurs PNA (Plans nationaux d'adaptation) en place d'ici 2025, avec l'inclusion dans chaque nouveau PNA ...

Parfois, l’innovation technologique peut provenir d’espace inattendus. Dans le développement de médicaments, cela signifie souvent l’intersection de technologies apparemment sans rapport ou de ...

Sometimes transformative technology comes from unexpected places. In drug development, that often means the intersection of seemingly unrelated technologies or esoteric areas of science. French ...

We want to build a healthier, more resilient world. We turn the impossible into the possible by discovering, developing, and delivering medicines and vaccines for millions of people around the world.

Bien que le phénomène de l’aggravation associée à l’inflammation neuroinflammatoire dans la sclérose en plaques soit largement reconnu par la communauté médicale, il reste encore beaucoup à faire pour ...

The phenomenon of smoldering-associated worsening in multiple sclerosis has been widely accepted by the medical community, yet much work is needed to fully integrate it into clinical practice.